Fasciolosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Fasciolosis}} {{PleaseHelp}} ==References== {{reflist|2}} Category:Helminthiases Category:Veterinary helminthology") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Fasciolosis}} | {{Fasciolosis}} | ||
{{CMG}} | |||
==Overview== | |||
==Medical therapy== | |||
===[[Anthelmintic]]s=== | |||
For high efficacy and safety, [[triclabendazole]] (Egaten®) in dose 10-12 mg/kg is drug of choice in human fasciolosis.<ref>Savioli, L., Chistulo, L., Montresor, A., 1999. New opportunities for the control of fascioliasis. Bull. WHO 77, 300.</ref> No drug alternatives are available for humans. On the other hand, [[nitazoxanide]] were successfully used in human fasciolosis treatment in Mexico.<ref>Rossignol, J.F., Abaza, H., Friedman, H., 1998. Successful treatment of human fascioliasis with nitazoxanide. Trans. Roy. Soc. Trop. Med. Hyg. 92, 103–104.</ref> | |||
Bithionol is another drug of choice used for treatment of [[fasciola hepatica]].<ref>Ramachandran, A., 2000. Pharmacology Recall.</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Helminthiases]] | [[Category:Helminthiases]] | ||
[[Category:Veterinary helminthology]] | [[Category:Veterinary helminthology]] | ||
Revision as of 15:08, 7 August 2015
|
Fasciolosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fasciolosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Fasciolosis medical therapy |
|
Risk calculators and risk factors for Fasciolosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical therapy
Anthelmintics
For high efficacy and safety, triclabendazole (Egaten®) in dose 10-12 mg/kg is drug of choice in human fasciolosis.[1] No drug alternatives are available for humans. On the other hand, nitazoxanide were successfully used in human fasciolosis treatment in Mexico.[2] Bithionol is another drug of choice used for treatment of fasciola hepatica.[3]
References
- ↑ Savioli, L., Chistulo, L., Montresor, A., 1999. New opportunities for the control of fascioliasis. Bull. WHO 77, 300.
- ↑ Rossignol, J.F., Abaza, H., Friedman, H., 1998. Successful treatment of human fascioliasis with nitazoxanide. Trans. Roy. Soc. Trop. Med. Hyg. 92, 103–104.
- ↑ Ramachandran, A., 2000. Pharmacology Recall.